Biotech Insights - Spring 2026

Why It Matters

Companies must adapt product‑change filings to avoid FDA delays, secure robust patent protection under evolving statutes, and structure California deals to comply with strict non‑compete and tax rules, all of which directly affect market speed and valuation.

Key Takeaways

• FDA classifies NDA changes as major, moderate, or minor
• Major/moderate changes require supplemental NDA; minor reported annually
• REGENXBIO win affirms patent eligibility for engineered host cells under PERA
• PERA seeks to codify patent‑eligibility rules, reducing litigation uncertainty
• California bans pre‑dispute jury‑trial waivers and limits non‑compete agreements in M&A

Pulse Analysis

The surge in GLP‑1 therapeutics has thrust post‑approval change reporting into the spotlight. The FDA now differentiates changes by their potential impact on a drug’s identity, strength, quality, purity, or potency, requiring supplemental NDAs for major and moderate alterations and relegating minor tweaks to the next annual report. This tiered approach, illustrated by Wegovy’s shift from injection to tablet, forces sponsors to meticulously assess each modification to prevent costly filing delays and maintain market momentum.

On the intellectual‑property front, the Federal Circuit’s recent ruling in REGENXBIO Inc. v. Sarepta Therapeutics marks a pivotal affirmation of patent eligibility for engineered host cells containing novel nucleic‑acid sequences. By interpreting the Patent Eligibility Restoration Act of 2025, the court signaled that genetically‑combined sequences that do not exist in nature are protectable, offering biotech firms a clearer path to secure exclusive rights. This decision curtails the uncertainty spawned by earlier Supreme Court cases and could accelerate investment in gene‑therapy platforms, as companies gain confidence that their core innovations are defensible.

California’s legal landscape adds another layer of complexity for life‑science M&A. The state’s Supreme Court has invalidated pre‑dispute jury‑trial waivers, and its Business and Professions Code strictly limits non‑competition clauses, allowing them only in narrow sale‑of‑goodwill scenarios. Coupled with a progressive tax regime—ranging from 1% to 13.3% for income and capital gains—deal makers must craft transaction structures that navigate these constraints, often opting for non‑California governing law or alternative dispute‑resolution mechanisms. Ignoring these nuances can stall deals or erode value, making thorough legal planning essential for successful acquisitions.